USFDA nod to Zydus Lifesciences glaucoma drug Acetazolamide
The drug is used with other medicines to reduce edema (excess fluid retention) and to help control seizures in certain types of epilepsy.
Ahmedabad: Pharma major, Zydus Lifesciences Limited, has announced that the company has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Acetazolamide Tablets USP, 125 mg and 250 mg (USRLD: Diamox Tablets, 125 mg and 250 mg). Acetazolamide is used to treat glaucoma, a condition in which increased pressure in the eye can lead...
Ahmedabad: Pharma major, Zydus Lifesciences Limited, has announced that the company has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Acetazolamide Tablets USP, 125 mg and 250 mg (USRLD: Diamox Tablets, 125 mg and 250 mg).
Acetazolamide is used to treat glaucoma, a condition in which increased pressure in the eye can lead to gradual loss of vision. Acetazolamide decreases the pressure in the eye. Acetazolamide is also used to reduce the severity and duration of symptoms (upset stomach, headache, shortness of breath, dizziness, drowsiness, and fatigue) of altitude (mountain) sickness.
The drug is used with other medicines to reduce edema (excess fluid retention) and to help control seizures in certain types of epilepsy.
The product will be manufactured at the group’s formulation manufacturing facility in Baddi, Himachal Pradesh (India).
Acetazolamide Tablets USP, 125 mg and 250 mg had annual sales of USD 16 mn in the United States (IQVIA MAT Dec. 2022). The group now has 358 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited), an Indian Pharmaceutical company is a fully integrated, global healthcare provider. The company was founded in the year 1952 by Mr. Ramanbhai B. Patel (late), a first-generation entrepreneur and a doyen in the field of Indian Pharmaceuticals.
Read also: Zydus Lifesciences bags USFDA nod for Levothyroxine Sodium for Injection for myxedema coma treatment
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd